DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
LY-2787106
1
Antibody
Investigational
Unknown
Unknown
Anemia
Hepcidin inhibitor
LY-2787106
×
Maximum Phase:
1
First Approval:
None
UNII:
Q87RWM02HX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 other
SONTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TUCOTUZUMAB CELMOLEUKIN
1
Antibody
Investigational
Unknown
Unknown
Ovarian Neoplasms
Epithelial cell adhesion molecule other
TUCOTUZUMAB CELMOLEUKIN
×
Maximum Phase:
1
First Approval:
None
UNII:
4ON7FF680U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
T84.66
1
Antibody
Investigational
Unknown
Unknown
Unknown
Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent
T84.66
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REGAVIRUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope glycoprotein B inhibitor
REGAVIRUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MILATUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Multiple Myeloma; Plasmacytoma
HLA-DR antigens-associated invariant chain antagonist
MILATUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
2OP4E0GC6V
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-61186372
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
JNJ-61186372
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CMB-401
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
CMB-401
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-1550
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RG-1550
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-100
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-100
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CDP-850
1
Antibody
Investigational
Unknown
Unknown
Unknown
Selectin E inhibitor
CDP-850
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LBY-135
1
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 10B agonist
LBY-135
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TELISOTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Hepatocyte growth factor receptor inhibitor
TELISOTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
R15ZW356HN
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TAVOLIMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
TAVOLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
4LU9B48U4D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUA33
1
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Cell surface A33 antigen binding agent
HUA33
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CROTEDUMAB
1
Antibody
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Glucagon receptor inhibitor
CROTEDUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
4JQ68PW6XF
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ULOCUPLUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Multiple Myeloma; Neoplasms; Waldenstrom Macroglobulinemia
C-X-C chemokine receptor type 4 inhibitor
ULOCUPLUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
7KNP87L4X4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TALQUETAMAB
1
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma; Hematologic Neoplasms
G-protein coupled receptor family C group 5 member D binding agent
TALQUETAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
4W3KFI3TN3
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AD-439
1
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope polyprotein GP160 inhibitor
AD-439
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MU-11-1F4 124I
1
Antibody
Investigational
Unknown
Unknown
Unknown
Light chain aggregates inhibitor
MU-11-1F4 124I
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
COFETUZUMAB PELIDOTIN
1
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Unknown
COFETUZUMAB PELIDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
249EAP69MT
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOS161721
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BOS161721
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FARALIMOMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interferon alpha-1/13 binding agent
FARALIMOMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MONO-DGA-RFB4
1
Antibody
Investigational
Unknown
Unknown
Lymphoma
CD22 binding agent
MONO-DGA-RFB4
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAR-1349
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
SAR-1349
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATINUMAB
1
Antibody
Investigational
Unknown
Unknown
Spinal Cord Injuries
Reticulon-4 inhibitor
ATINUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
9UBQ62RW32
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
4G7XH22
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Lymphoma
Unknown
4G7XH22
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BUDIGALIMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma
Programmed cell death protein 1 inhibitor
BUDIGALIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
6VDO4TY3OO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KHK-2866
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Proheparin-binding EGF-like growth factor inhibitor
KHK-2866
×
Maximum Phase:
1
First Approval:
None
UNII:
111EN0IJ7C
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VIBECOTAMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
VIBECOTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
JD56EJA59S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONGERICIMAB
1
Antibody
Investigational
Unknown
Unknown
Hypercholesterolemia; Hyperlipidemias
Unknown
ONGERICIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
X126G5DZ36
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MNRP1685A
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MNRP1685A
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LINTUZUMAB ACTINIUM AC-225
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LINTUZUMAB ACTINIUM AC-225
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMURUTAMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell
Unknown
PIMURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5V1Y8T4RB6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7636
1
Antibody
Investigational
Unknown
Unknown
Unknown
Endothelin receptor ET-B binding agent
RG-7636
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
8
9
10
11
12
13
14
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA